Please assess the completion status of the following clinical trial:

Trial Title: Bone MicroArchitecture Abatacept (BMA2)

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Signed and dated informed consent form,~* Age ≥ 18 years,~* Rheumatoid arthritis diagnosis according to ACR/EULAR 2010 criteria~* Abatacept therapy sub-cutaneous required according EULAR recommendations~* Patients affiliated to health insurance~Exclusion Criteria:~* Other arthritis than rheumatoid arthritis,~* Contraindication to abatacept,~* Concomitant treatment with zoledronic acid (Aclasta®) or denosumab (Prolia®),~* Injection intravenously or intra-articular at the 2nd and 3rd metacarpophalangeal joint of the dominant hand during the 3 months prior to inclusion,~* Prior or planned joint surgery at the 2nd or 3rd metacarpophalangeal joint of the dominant hand over the one year study,~* No recent used of high density contrast material,~* Pregnancy or breastfeeding.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Patients with rheumatoid arthritis. (Type: None): Rheumatoid arthritis diagnosis according to ACR (American College of Radiology)/EULAR 2010 classification criteria.

Based on this trial design, predict the completion outcome and termination type (if applicable).